Abstract
The ability of proteins to aggregate to form well‐organized b‐sheet rich amyloid fibrils is increasingly viewed as a general if regrettable property of the polypeptide chain. Aggregation leads to diseases such as amyloidosis and neurodegeneration in humans and various mammalian species but is also found in a functional variety in both animals and microbes. However, there are to our knowledge no reports of amyloid formation in plants. Plants are also the source of a large number of aggregation‐inhibiting compounds. We reasoned that the two phenomena are connected and that the longer‐lived the plant, the more efficiently it can suppress unwanted protein aggregation. In support of this, we show that while protein extracts from the sugar maple tree A. saccharum fibrillate readily on their own, this process is efficiently abolished by addition of small molecule extracts from the same plant. Further analysis of 44 plants showed a correlation between plant longevity and ability to inhibit protein aggregation. Extracts from the best performing plant, the sugar maple, were subjected to chromatographic fractionation, leading to the identification of a large number of compounds, many of which were shown to inhibit aggregation in vitro. We suggest that plants have been under evolutionary pressure to maintain an efficient collection of aggregation‐inhibiting metabolites; consequently, long‐lived plants may be particularly appropriate sources of new anti‐aggregation compounds with therapeutic potential.Support or Funding InformationD.E.O. was supported by a grant to D.E.O. from The Danish Council for Independent Research | Technology and Production Sciences (grant number: 12–126186), and Parkinson Foreningen (the Danish Parkinson Society). Rothamsted Research receives grant‐aided support from the Biotechnology and Biological Sciences Research Council (BBSRC) of the United Kingdom.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Highlights
Since the first discovery of plaque in the brains of patients suffering from Alzheimer’s disease (Masters et al, 1985), a number of proteins have been shown to form insoluble β-sheet-rich structures called amyloid or fibrils under physiological conditions (Chiti and Dobson, 2006)
thioflavin T (ThT) fluorescence increased for some protein fractions over a 5-day incubation period (Supplementary Figure S2), consistent with general formation of fibrils
There were no fibrils in F27 before extraction according to transmission electron microscopy (TEM) (Figure 1B, left), but fibril-like structures were observed after 5 days of incubation [Figure 1B(I)]
Summary
Since the first discovery of plaque in the brains of patients suffering from Alzheimer’s disease (Masters et al, 1985), a number of proteins have been shown to form insoluble β-sheet-rich structures called amyloid or fibrils under physiological conditions (Chiti and Dobson, 2006). Among these are proteins related to common diseases of lifestyle and aging such as type II diabetes (Pillay and Govender, 2013), Alzheimer’s disease, and Parkinson’s disease (Poggiolini et al, 2013) as well as rare genetic disease such as FAS4 mediated corneal dystrophy (Han et al, 2010; Stenvang et al, 2018). Examples limit themselves to a tobacco plant expressing a foreign protein (from maize) in the chloroplast (Villar-Pique et al, 2010), a coconut antimicrobial peptide which can fibrillate in aqueous buffer (Gour et al, 2016), a soya β-conglycinin subunit which fibrillates in vitro after heat treatment (Wang et al, 2011), and a protein fragment that fibrillates in vitro (Garvey et al, 2013)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.